

RESEARCH MONOGRAPH . COMPOUND PROFILE

Memantine

A 3,5-dimethyladamantane derivative developed by Merz Pharmaceuticals as a moderate-affinity, voltage-dependent, uncompetitive NMDA receptor open-channel blocker approved for moderate-to-severe Alzheimer's disease, distinguished from high-affinity NMDA antagonists by rapid off-rate kinetics that permit preservation of physiological synaptic transmission while attenuating tonic excitotoxic glutamatergic signaling.

DOCUMENT	KDC-MN-1357
ISSUED	2026-05-10
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Uncompetitive NMDA receptor antagonist with ancillary 5-HT3 antagonist and alpha-7 nicotinic receptor activity

ABSTRACT

Memantine (1-amino-3,5-dimethyladamantane; CAS 19982-08-2; molecular formula $C_{12}H_{21}N$; molecular weight 179.30) is a moderate-affinity, uncompetitive, voltage-dependent, open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor, approved in the European Union (2002) and the United States (2003) for the treatment of moderate-to-severe Alzheimer's disease. The compound is an adamantane derivative structurally related to the antiviral agent amantadine, first synthesized and patented by Eli Lilly and Company in 1968 as a potential antidiabetic agent, subsequently identified as possessing central nervous system activity in the early 1970s by Merz Pharmaceuticals, and characterized as an NMDA receptor channel blocker by Bormann in 1989 [1]. The pharmacological distinction of memantine from high-affinity NMDA channel blockers such as phencyclidine, dizocilpine (MK-801), and ketamine rests on three properties: moderate binding affinity (IC_{50} approximately 1 micromolar at resting membrane potential), strong voltage dependence that ensures rapid unblocking upon physiological depolarization, and fast open-channel blocking and unblocking kinetics (time constant of unblock approximately 5 seconds) [2, 3]. These kinetic properties allow memantine to attenuate the tonic, pathologically elevated glutamatergic signaling associated with excitotoxic neurodegeneration while preserving the transient, high-amplitude synaptic NMDA receptor activation required for long-term potentiation and normal cognitive function. In addition to the primary NMDA receptor mechanism, memantine acts as a non-competitive antagonist of the serotonin 5-HT₃ receptor at

concentrations comparable to its NMDA receptor affinity (IC₅₀ approximately 1 to 2 micromolar) [4] and as a non-competitive antagonist of the alpha-7 nicotinic acetylcholine receptor (IC₅₀ approximately 0.34 to 5 micromolar depending on assay conditions) [5]. Weak agonist activity at the sigma-1 receptor (K_i approximately 2.6 micromolar) has been reported but is unlikely to contribute at therapeutic plasma concentrations [6].

Pharmacokinetics in humans are characterized by near-complete oral bioavailability (approximately 100 percent), a long plasma elimination half-life of 60 to 80 hours permitting once- or twice-daily dosing, minimal hepatic cytochrome P450-mediated metabolism, and predominantly renal elimination with approximately 48 percent of the administered dose excreted unchanged in urine through pH-dependent tubular reabsorption and active tubular secretion [7, 8]. The compound is well tolerated at the approved dose of 20 mg per day; the principal adverse events in registration trials were dizziness, headache, confusion, and constipation, occurring at rates comparable to or modestly exceeding placebo [9, 10]. Two pivotal registration trials established efficacy: the Reisberg et al. (2003) study in 252 patients with moderate-to-severe Alzheimer's disease demonstrated significant benefit over placebo on the Severe Impairment Battery (SIB) and the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) over 28 weeks [9], and the Tariot et al. (2004) study in 404 patients already receiving stable donepezil demonstrated that the addition of memantine produced significant improvement in cognitive, functional, behavioral, and global measures compared to placebo plus donepezil [10]. Memantine is marketed as Namenda (Forest Laboratories, now Allergan/AbbVie) in the United States, as Axura (Merz) and Ebixa (Lundbeck) in Europe, and under multiple

generic names globally. An extended-release formulation (Namenda XR, 28 mg once daily) was approved in 2010, and a fixed-dose combination of memantine extended-release and donepezil (Namzaric, 28 mg/10 mg) was approved in 2014. This monograph reviews the chemistry, synthesis, and structural pharmacology of memantine; the multi-target receptor pharmacology with emphasis on the NMDA receptor mechanism; comprehensive human pharmacokinetics; preclinical neuroprotection and cognition pharmacology; the clinical evidence base across Alzheimer's disease, vascular dementia, neuropathic pain, and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signal; and a comparative assessment of five therapeutic alternatives against memantine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Memantine.

Marketed names: Namenda, Namenda XR (Forest Laboratories/Allergan/AbbVie; United States), Axura (Merz Pharmaceuticals; Germany, other European markets), Ebixa (H. Lundbeck; European Union, Canada, Australia), Akatinol (Russia, Commonwealth of Independent States), Memary (Daiichi Sankyo; Japan), Namzaric (fixed-dose combination with donepezil; Allergan/AbbVie; United States). Multiple generic formulations are available globally following patent expiration.

Development codes: MRZ 2/145 (Merz Pharmaceuticals). The Merz development code is the canonical identifier in the early German pharmacology literature and in the original dementia clinical trial protocols.

Chemical Abstracts Service registry numbers: 19982-08-2 (free base), 41100-52-1 (hydrochloride salt). The hydrochloride salt is the formulated pharmaceutical material for oral administration; the free base is the synthetic intermediate and the form used in most research-grade preparations.

International Union of Pure and Applied Chemistry name: 3,5-dimethyladamantan-1-amine. The compound is the 3,5-dimethyl derivative of 1-aminoadamantane (amantadine), sharing the adamantane cage hydrocarbon core with amantadine, rimantadine, and several other pharmacologically active adamantane derivatives.

1.2 Structural class and chemistry

Memantine is an aminoadamantane derivative characterized by a tricyclo[3.3.1.1(3,7)]decane (adamantane) cage bearing an amino group at the 1-position and methyl substituents at the 3- and 5-positions. The adamantane cage confers lipophilicity, metabolic stability, and the geometric properties required for channel blocking activity at the NMDA receptor pore. The structural class places memantine within the aminoadamantane family that includes amantadine (1-

aminoadamantane; antiviral and antiparkinsonian), rimantadine (alpha-methyl-1-adamantanemethylamine; antiviral), and several experimental neuroprotective agents [11].

Molecular formula: C₁₂H₂₁N (free base); C₁₂H₂₂ClN (hydrochloride salt).

Exact mass: 179.1674 g/mol (free base, monoisotopic).

Molecular weight: 179.30 g/mol (free base); 215.76 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder. The hydrochloride salt is freely soluble in water, soluble in methanol and ethanol, and sparingly soluble in apolar organic solvents. Melting point of the hydrochloride salt is approximately 290 to 295 degrees Celsius. The free base is a volatile amine with a characteristic aminic odor; the hydrochloride salt is odorless and non-hygroscopic under standard storage conditions.

Stereochemistry: Memantine contains no stereocenters. The adamantane cage is symmetric with respect to the 1-amino and 3,5-dimethyl substitution pattern, and the compound exists as a single achiral species. No enantiomeric or diastereomeric considerations apply to compound identity or quality verification.

pKa: The primary amine has a pKa of approximately 10.7, meaning the compound is predominantly protonated (cationic) at physiological pH (7.4). The charged ammonium form is the species that occupies the NMDA receptor channel pore; the voltage dependence of block is a direct consequence of the movement of the charged blocker in the transmembrane electric field [2, 3].

1.3 Synthesis

The synthesis of memantine proceeds from adamantanone (2-adamantanone) or from 1-adamantanol through established adamantane functionalization chemistry. The classical route involves Ritter reaction of 1,3-dimethyladamantane with acetonitrile in the presence of a strong acid (sulfuric acid or trifluoroacetic acid) to introduce the nitrogen at the bridgehead 1-position, followed by hydrolysis of the intermediate acetamide to yield the free amine [12]. Alternative routes include the direct amination of 1-bromo-3,5-dimethyladamantane with potassium phthalimide followed by hydrazinolysis (Gabriel synthesis), and the Leuckart-Wallach reductive amination of 3,5-dimethyl-1-adamantanol with formamide followed by acid hydrolysis. Industrial syntheses optimize the Ritter reaction for yield (typically 60 to 80

percent) and purity, with the product purified by recrystallization of the hydrochloride salt from ethanol-diethyl ether mixtures or from isopropanol. The hydrochloride salt is prepared by treatment of the free base with hydrochloric acid in a suitable solvent (diethyl ether, isopropanol) followed by filtration and recrystallization. Pharmaceutical-grade memantine hydrochloride is manufactured to pharmacopoeial specifications (United States Pharmacopeia, European Pharmacopoeia) with purity greater than 99.0 percent by area-percent high-performance liquid chromatography and controlled residual solvent and heavy metal content.

2. Abstract

Memantine (3,5-dimethyladamantan-1-amine) is the first and only clinically approved moderate-affinity, uncompetitive, voltage-dependent NMDA receptor channel blocker for the treatment of dementia. Approved in 2002 in the European Union and 2003 in the United States for moderate-to-severe Alzheimer's disease, memantine occupies a unique pharmacological position among clinically available dementia therapeutics as the sole agent that targets the glutamatergic excitotoxicity pathway rather than the cholinergic deficit pathway addressed by the acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine [9, 10, 13].

The pharmacological rationale for memantine in Alzheimer's disease rests on the glutamate excitotoxicity hypothesis of neurodegeneration: in Alzheimer's disease and related dementias, chronic low-level elevation of extracellular glutamate produces tonic activation of NMDA receptors, sustained calcium influx through the receptor-associated cation channel, activation of calcium-dependent proteases, lipases, and endonucleases, mitochondrial dysfunction, and progressive neuronal death [2, 14]. High-affinity NMDA channel blockers such as phencyclidine and dizocilpine (MK-801) effectively prevent excitotoxic calcium influx but also block the physiological NMDA receptor activation required for synaptic plasticity, learning, and memory, producing psychotomimetic effects, cognitive impairment, and neurotoxicity (Olney lesions) that preclude therapeutic use [15]. Memantine's moderate affinity, strong voltage dependence, and fast kinetics allow it to be displaced from the channel by the physiological depolarization that accompanies normal synaptic transmission, thereby preserving long-term potentiation and normal cognitive signaling while attenuating the chronic pathological activation that drives excitotoxicity [2, 3].

Two pivotal Phase 3 clinical trials established the efficacy of memantine in moderate-to-severe Alzheimer's disease. The Reisberg et al. (2003) monotherapy trial in 252 patients demonstrated statistically significant benefit on the Severe Impairment Battery (SIB; treatment difference 5.7 points, $p = 0.002$) and on the CIBIC-Plus global assessment ($p = 0.06$ on the primary analysis, $p = 0.03$ on the observed cases analysis) over 28 weeks [9]. The Tariot et al. (2004) combination therapy trial in 404 patients receiving stable donepezil demonstrated that the addition of memantine produced significant improvement on the SIB (treatment difference

3.4 points, p less than 0.001), on activities of daily living (ADCS-ADL19, treatment difference 1.4 points, $p = 0.03$), on the Neuropsychiatric Inventory (NPI, treatment difference 3.8 points, $p = 0.002$), and on the CIBIC-Plus ($p = 0.03$) compared to placebo plus donepezil [10]. Meta-analyses of six-month memantine trials have confirmed modest but statistically significant benefits across cognitive, functional, global, and behavioral domains in moderate-to-severe Alzheimer's disease, with less consistent evidence of benefit in mild-to-moderate disease [16, 17].

The pharmacokinetic profile of memantine is characterized by near-complete oral bioavailability, a long elimination half-life of 60 to 80 hours, minimal hepatic metabolism, and renal elimination with pH-dependent tubular reabsorption. The compound is well tolerated at the approved dose of 20 mg per day (immediate-release) or 28 mg per day (extended-release), with adverse event rates comparable to placebo in controlled trials [7, 8].

This monograph documents the chemistry, synthesis, and structural pharmacology of memantine; the multi-target receptor pharmacology in molecular and electrophysiological detail; comprehensive human pharmacokinetics; the preclinical neuroprotection and cognition literature; the clinical evidence base across approved and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signal; and a structured comparative assessment of five therapeutic alternatives (donepezil, rivastigmine, galantamine, riluzole, and dextromethorphan-quinidine) against memantine on five competency standards.

3. Discovery and Development History

3.1 Origin

Memantine was first synthesized and patented by Eli Lilly and Company in 1968 (United States Patent 3,391,142) as part of a structure-activity investigation of adamantane derivatives for potential antidiabetic activity [18]. The compound was evaluated as a hypoglycemic agent and was found to be inactive for this indication. In the early 1970s, Merz and Company (later Merz Pharmaceuticals) in Frankfurt am Main, Germany, identified central nervous system activity in memantine during preclinical screening and initiated development of the compound for neurological indications. The initial clinical investigations by Merz focused on spasticity, Parkinson's disease, and drug-induced extrapyramidal symptoms, indications in which the structurally related amantadine was already established [19].

3.2 Identification as an NMDA receptor antagonist

The mechanism of action of memantine remained uncertain for approximately two decades after the initial Merz clinical development. In 1989, Bormann published the demonstration that memantine is a potent blocker of NMDA receptor channels in mouse hippocampal neurons, with an IC₅₀ of approximately 1 micromolar at a holding potential of minus 70 millivolts [1]. This characterization placed memantine in the NMDA receptor antagonist class alongside the dissociative anesthetics phencyclidine and ketamine and the experimental compound dizocilpine (MK-801), but with the critical distinction that memantine's moderate affinity and rapid kinetics produced a qualitatively different blockade pattern. The subsequent work of Chen and Lipton (1997) and Chen et al. (1998) at Harvard Medical School formally characterized the voltage dependence, the open-channel blocking mechanism, and the rapid on-off kinetics that distinguish memantine from the high-affinity NMDA channel blockers [20, 21]. The Parsons, Danysz, and Quack (1999) comprehensive review at Merz Pharmaceuticals consolidated the pharmacological rationale for memantine as a therapeutically tolerable NMDA receptor antagonist and articulated the excitotoxicity hypothesis as the basis for clinical development in Alzheimer's disease [2].

3.3 Clinical development for dementia

The first clinical trial of memantine in dementia was conducted in Germany in 1986 by Merz Pharmaceuticals, predating the formal characterization of the NMDA receptor mechanism. Early clinical studies in the late 1980s and early 1990s in Germany demonstrated modest cognitive and functional benefits in patients with dementia, supporting continued development [22]. Memantine was first marketed for dementia in Germany in 1989 under the trade name Axura, based on the German clinical evidence and the emerging understanding of the glutamatergic excitotoxicity mechanism.

The pivotal registration studies for the European Union and United States approvals were conducted in the late 1990s and early 2000s. The Winblad and Poritis (1999) study was a 12-week double-blind placebo-controlled trial of memantine 10 mg per day in 166 patients with severe dementia (including both Alzheimer's disease and vascular dementia), demonstrating significant improvement on the Clinical Global Impression of Change and on functional measures [23]. The Reisberg et al. (2003) study in 252 community-dwelling patients with moderate-to-severe Alzheimer's disease (Mini-Mental State Examination score 3 to 14) was the first of two pivotal Phase 3 trials supporting the United States registration; patients receiving memantine 20 mg per day showed significant benefit on the SIB and CIBIC-Plus compared to placebo over 28 weeks [9].

3.4 Regulatory approvals and subsequent development

The European Medicines Agency approved memantine (Ebixa, Axura) in May 2002 for the treatment of moderate-to-severe Alzheimer's disease. The United States Food and Drug Administration approved memantine (Namenda) in October 2003, also for moderate-to-severe Alzheimer's disease. The approved dose in both jurisdictions is 20 mg per day (10 mg twice daily), titrated upward from 5 mg per day over approximately 3 to 4 weeks.

In June 2010, the FDA approved Namenda XR, an extended-release formulation of memantine at 28 mg once daily, providing the convenience of once-daily dosing and a higher peak-trough ratio. In December 2014, the FDA approved Namzaric, a fixed-dose combination of memantine extended-release 28 mg and donepezil 10 mg in a single capsule, for moderate-to-severe Alzheimer's disease in patients stabilized on both components.

The compound is now off-patent in most major jurisdictions. Generic memantine immediate-release and extended-release formulations are available from multiple manufacturers globally. The originator Merz Pharmaceuticals continues to market Axura and Akatinol in selected European and Commonwealth of Independent States markets; Lundbeck markets Ebixa in Canada, Australia, and multiple European markets; Daiichi Sankyo markets Memary in Japan.

4. Mechanism of Action

Memantine is a multi-target ligand whose therapeutic activity is attributed principally to NMDA receptor channel blockade, with ancillary pharmacological activities at the 5-HT₃ receptor, the α -7 nicotinic acetylcholine receptor, and the sigma-1 receptor. These activities operate at overlapping concentration ranges in vitro, but the NMDA receptor mechanism is the target for which the strongest mechanistic, preclinical, and clinical evidence supports the therapeutic effect.

4.1 NMDA receptor channel blockade

The NMDA receptor is a heterotetrameric ligand-gated cation channel composed of two obligatory GluN1 subunits and two GluN2 (GluN2A, GluN2B, GluN2C, or GluN2D) or GluN3 subunits. The receptor is activated by the co-agonists glutamate (binding the GluN2 subunit) and glycine or D-serine (binding the GluN1 subunit) and is subject to voltage-dependent block by extracellular magnesium ions at resting membrane potential. Removal of the magnesium block by depolarization permits calcium and sodium influx through the channel pore, driving the calcium-dependent signaling cascades that underlie synaptic plasticity, long-term potentiation, and memory consolidation [14].

Memantine blocks the open NMDA receptor channel by binding to a site within the channel pore that overlaps with the magnesium binding site. The blocking mechanism is uncompetitive: memantine can only access the binding site when the channel is in the open conformation, and increasing agonist (glutamate) concentration does not overcome the block but rather increases the proportion of channels in the open state available for blocking [2, 3]. The critical pharmacological properties that distinguish memantine from the high-affinity NMDA channel blockers are:

Moderate affinity. The IC₅₀ of memantine for NMDA receptor channel block is approximately 1 micromolar at a holding potential of minus 70 millivolts and at physiological magnesium concentrations. This is approximately 10- to 100-fold lower affinity than phencyclidine (IC₅₀ approximately 20 to 50 nanomolar) and dizocilpine (IC₅₀ approximately 3 to 10 nanomolar) [1, 2]. The moderate affinity ensures that memantine does not accumulate irreversibly in the channel and can be displaced by the large depolarizations that accompany normal synaptic events.

Strong voltage dependence. Memantine blocking of the NMDA channel is strongly voltage-dependent, with the Woodhull electrical distance parameter (δ) of approximately 0.8, similar to magnesium and substantially greater than phencyclidine (δ approximately 0.6) or MK-801 (δ approximately 0.5) [2, 3]. The strong voltage dependence means that physiological synaptic depolarization rapidly expels memantine from the channel, restoring normal channel function during the brief, high-amplitude synaptic events that drive long-term potentiation.

Fast kinetics. The time constant for memantine unblocking from the open NMDA channel is approximately 5 seconds at minus 70 millivolts, compared to approximately 45 seconds for MK-801 and approximately 15 seconds for phencyclidine [2]. The fast kinetics ensure that memantine block is rapidly reversible on the timescale of synaptic events (milliseconds to seconds), preventing the accumulation of blocker in the channel that produces the psychotomimetic effects and neurotoxicity of the high-affinity agents.

Preferential blockade of extrasynaptic receptors. Xia et al. (2010) demonstrated that memantine at therapeutically relevant concentrations preferentially blocks tonically activated extrasynaptic NMDA receptors (which mediate excitotoxic signaling) over synaptically activated receptors (which mediate physiological plasticity), with an IC_{50} of approximately 22 nanomolar at extrasynaptic receptors versus approximately 1 micromolar at synaptic receptors under physiological conditions with ambient magnesium [24]. This selectivity provides a molecular basis for the therapeutic window: memantine attenuates the chronic, low-level extrasynaptic excitotoxic drive while preserving the phasic, high-amplitude synaptic signaling required for cognition.

The composite mechanism therefore allows memantine to function as a pathological signal filter: the compound occupies the NMDA channel under conditions of tonic, low-level glutamatergic activation (the excitotoxic pathological state in Alzheimer's disease) but is expelled from the channel by the transient, large-amplitude depolarizations that constitute normal synaptic communication [2, 3, 14].

4.2 Serotonin 5-HT₃ receptor antagonism

Memantine acts as a non-competitive antagonist of the serotonin 5-HT₃ receptor with an IC_{50} of approximately 1 to 2 micromolar, comparable to its affinity for the NMDA receptor channel [4]. The 5-HT₃ receptor is a member of the Cys-loop superfamily of ligand-gated ion channels (the same superfamily as the nicotinic acetyl-

choline receptor and the GABA-A receptor) and mediates rapid excitatory serotonergic neurotransmission. The 5-HT₃ antagonist activity of memantine is mechanistically analogous to the channel-blocking activity at NMDA receptors and likely involves occlusion of the 5-HT₃ receptor cation channel. The therapeutic significance of this activity is uncertain; 5-HT₃ antagonists (ondansetron, granisetron, tropisetron) are principally antiemetics, and the 5-HT₃ antagonism of memantine may contribute to the relatively low incidence of nausea reported in clinical trials despite the gastrointestinal effects characteristic of other centrally active compounds [4].

4.3 Alpha-7 nicotinic acetylcholine receptor antagonism

Memantine acts as a non-competitive antagonist at the alpha-7 subtype of the neuronal nicotinic acetylcholine receptor, with reported IC₅₀ values ranging from 0.34 micromolar to 5 micromolar depending on the assay system and the degree of receptor desensitization [5]. Bhatt et al. (2013) reported that memantine blocks alpha-7 nicotinic receptors more potently than NMDA receptors in rat hippocampal neurons under physiological conditions, raising the question of whether alpha-7 nicotinic antagonism contributes to or detracts from the cognitive effects of memantine [5]. The alpha-7 nicotinic receptor is implicated in cognitive function (through its role in cortical and hippocampal cholinergic signaling), in the cholinergic anti-inflammatory pathway (through macrophage alpha-7 activation), and in sensory gating. Antagonism at this receptor could theoretically oppose the procognitive effects of acetylcholinesterase inhibitors with which memantine is commonly co-prescribed. However, clinical evidence from the Tariot et al. (2004) combination trial demonstrated that memantine augmented rather than diminished the cognitive benefit of donepezil, suggesting that the net pharmacological effect of memantine in combination with cholinesterase inhibitors is beneficial despite the alpha-7 antagonism [10]. The explanation may involve the concentration-dependent balance between NMDA receptor neuroprotection (beneficial) and alpha-7 antagonism (potentially counterproductive), with the former predominating at therapeutic concentrations.

4.4 Sigma-1 receptor agonism

Memantine acts as a weak agonist at the sigma-1 receptor with a K_i of approximately 2.6 micromolar [6]. The sigma-1 receptor is an endoplasmic reticulum chaperone protein involved in calcium signaling, neuroprotection, and neuroplasticity.

Sigma-1 receptor agonists have demonstrated neuroprotective and antidepressant properties in preclinical models. However, the therapeutic concentration of memantine at the approved dose of 20 mg per day produces steady-state plasma concentrations of approximately 0.5 to 1 micromolar, which is below the sigma-1 receptor K_i . The contribution of sigma-1 receptor agonism to the clinical effect of memantine is therefore uncertain and likely minimal at approved doses [6].

4.5 Downstream neuroprotective cascades

The NMDA receptor blockade by memantine produces several downstream neuroprotective effects that extend beyond the immediate reduction in excitotoxic calcium influx. These include reduction of tau hyperphosphorylation through attenuation of calcium-dependent kinase activation, reduction of oxidative stress through decreased mitochondrial calcium loading, preservation of mitochondrial membrane potential, upregulation of brain-derived neurotrophic factor (BDNF) expression, and modulation of autophagy pathways [14, 25]. These downstream effects are documented principally in preclinical systems and provide mechanistic support for the disease-modifying potential of memantine beyond its symptomatic cognitive effects, though no clinical trial has demonstrated disease modification as measured by biomarker or neuropathological endpoints.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Memantine is well absorbed from the gastrointestinal tract after oral administration. Oral bioavailability is approximately 100 percent, reflecting the absence of significant first-pass hepatic metabolism [7, 8]. Time to peak plasma concentration after oral administration of the immediate-release formulation is approximately 3 to 7 hours. Food does not significantly affect the rate or extent of absorption. Maximum plasma concentration after a single 20 mg oral dose is approximately 22 nanograms per milliliter (approximately 0.12 micromolar) [7].

The extended-release formulation (Namenda XR, 28 mg once daily) produces peak plasma concentrations approximately 9 to 12 hours after administration, with a flatter peak-trough profile compared to the immediate-release formulation. Steady-state plasma concentrations with the extended-release formulation are bioequivalent to those achieved with the immediate-release formulation at the approved dose of 10 mg twice daily [26].

5.2 Distribution

Memantine has a large volume of distribution of approximately 9 to 11 liters per kilogram, reflecting extensive tissue partitioning consistent with the compound's lipophilicity and basic amine character [7, 8]. Plasma protein binding is approximately 45 percent, lower than many centrally acting compounds. The compound crosses the blood-brain barrier; cerebrospinal fluid concentrations in Alzheimer's disease patients on chronic 20 mg per day dosing are approximately 50 to 60 percent of simultaneous plasma concentrations, consistent with moderate central nervous system penetration [27]. The CSF concentration at steady state (approximately 0.02 to 0.06 micromolar) is within the range of the preferential extrasynaptic NMDA receptor blockade described by Xia et al. (2010) [24].

5.3 Metabolism

Memantine undergoes minimal hepatic metabolism. The cytochrome P450 enzyme system does not play a significant role in memantine biotransformation, and the compound is neither a significant inhibitor nor inducer of CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP3A4, or other major CYP isoforms at therapeutic concentrations [7, 8]. Three polar metabolites are formed in small quantities: the N-glucuronide conjugate, 6-hydroxy-memantine, and 1-nitroso-deaminated memantine. None of these metabolites possesses significant NMDA receptor antagonist activity. The absence of CYP-dependent metabolism is a clinically important distinguishing feature from other centrally acting compounds and substantially reduces the potential for pharmacokinetic drug-drug interactions.

5.4 Elimination

Memantine elimination is predominantly renal. Approximately 48 percent of an administered dose is excreted unchanged in urine [7, 8]. The remainder is excreted as the three polar metabolites described above. Renal clearance involves active tubular secretion moderated by pH-dependent tubular reabsorption: the basic amine (pKa approximately 10.7) is predominantly ionized at physiological urine pH and is not reabsorbed; alkalinization of urine (pH greater than 8) reduces ionization, increases tubular reabsorption, and can substantially prolong the elimination half-life and increase plasma concentrations [7, 8].

The plasma elimination half-life is 60 to 80 hours, consistent with the large volume of distribution and the moderate total body clearance. The long half-life permits once-daily dosing with the extended-release formulation and supports stable plasma concentrations with twice-daily dosing of the immediate-release formulation. Steady-state plasma concentrations are achieved in approximately 2 to 3 weeks of chronic dosing.

Renal impairment substantially affects memantine pharmacokinetics. In patients with moderate renal impairment (creatinine clearance 30 to 49 mL/min), the AUC is increased by approximately 40 percent and dose reduction to 10 mg per day (immediate-release) or 14 mg per day (extended-release) is recommended. In patients with severe renal impairment (creatinine clearance 5 to 29 mL/min), the AUC is increased by approximately 75 percent and a further dose reduction to 5 mg

twice daily (or avoidance) is recommended in prescribing labels [7, 8]. Hepatic impairment has minimal effect on memantine pharmacokinetics owing to the predominantly renal elimination.

5.5 Routes of administration

The approved route of administration is oral. The immediate-release formulation is available as 5 mg and 10 mg tablets and as a 2 mg/mL oral solution. The extended-release formulation is available as 7 mg, 14 mg, 21 mg, and 28 mg capsules that may be opened and sprinkled on applesauce for patients with dysphagia. The fixed-dose combination (Namzaric) is supplied as capsules containing 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, and 28 mg/10 mg of memantine extended-release and donepezil, respectively. Intravenous and intramuscular formulations have not been developed for clinical use; parenteral administration is limited to preclinical research.

5.6 Special populations

Geriatric pharmacokinetics are similar to the general adult population after adjustment for renal function. Pediatric pharmacokinetics have been characterized in limited studies; memantine has been investigated in pediatric autism spectrum disorder and attention-deficit/hyperactivity disorder but is not approved for pediatric use. Pregnancy data are limited; the compound is rated FDA Pregnancy Category B (animal studies show no teratogenicity at clinically relevant doses; no adequate human studies). Use in lactation is discouraged owing to limited data and the long half-life.

6. Preclinical Pharmacology

6.1 Neuroprotection models

Memantine has been extensively characterized in preclinical neuroprotection models that support the glutamate excitotoxicity rationale for its clinical use. In primary neuronal cultures, memantine at 1 to 10 micromolar protects against NMDA-induced excitotoxic cell death with efficacy comparable to or exceeding that of MK-801, while preserving NMDA receptor-dependent long-term potentiation at the same concentrations where MK-801 abolishes it [2, 20, 21]. In the retinal ganglion cell NMDA excitotoxicity model, memantine at clinically relevant concentrations (1 micromolar) provided significant neuroprotection while MK-801 produced paradoxical neurotoxicity at similar protective concentrations [20].

In vivo, memantine has demonstrated neuroprotective efficacy in rodent models of focal and global cerebral ischemia, traumatic brain injury, and chronic neurodegenerative disease. In the rat middle cerebral artery occlusion model, memantine at 20 mg/kg intraperitoneal administered 1 to 2 hours after occlusion onset significantly reduced infarct volume [28]. In transgenic mouse models of Alzheimer's disease (APP/PS1 double transgenic, 3xTg-AD), chronic memantine administration reduced amyloid plaque burden, attenuated neuroinflammation (microglial activation, proinflammatory cytokine expression), and preserved synaptic density in hippocampal and cortical regions [25, 29].

6.2 Cognitive and behavioral models

In the Morris water maze spatial learning paradigm, memantine at 1 to 10 mg/kg improved learning and memory in aged rats and in rats treated with scopolamine, beta-amyloid peptide injection, or chronic stress-induced hippocampal damage [30]. The dose-response relationship is non-monotonic (inverted U-shaped): low to moderate doses (1 to 10 mg/kg in rodents, corresponding to clinical doses of 10 to 20 mg/day) improve cognitive performance, while higher doses (30 mg/kg or above) impair performance through excessive NMDA receptor blockade, consistent with the pharmacological principle that too little and too much NMDA receptor activation are both detrimental to cognitive function [2, 31].

In the novel object recognition paradigm, memantine at 3 to 10 mg/kg improved recognition memory in scopolamine-treated and aged rats. In the radial arm maze, chronic memantine at 5 mg/kg improved working memory errors in aged rats. The PHA-543613 and memantine combination study demonstrated synergistic cognitive enhancement in aged rats when memantine was co-administered with the alpha-7 nicotinic agonist, suggesting complementary mechanisms through which NMDA receptor modulation and alpha-7 nicotinic activation can produce additive or synergistic cognitive benefit [32].

6.3 Pain models

Memantine has been evaluated in multiple preclinical pain models based on the role of NMDA receptors in central sensitization and wind-up of dorsal horn nociceptive neurons. In the rat chronic constriction injury model of neuropathic pain, memantine at 10 to 20 mg/kg attenuated mechanical allodynia and thermal hyperalgesia [33]. In the formalin test, memantine reduced second-phase (centrally mediated) nociceptive behavior without affecting first-phase (peripheral) responses, consistent with a central NMDA receptor-mediated mechanism [34]. These preclinical findings have supported clinical investigation of memantine in neuropathic pain and fibromyalgia, though the clinical translation has been inconsistent.

7. Clinical Evidence Base

7.1 Moderate-to-severe Alzheimer's disease (approved indication)

The clinical evidence base for memantine in moderate-to-severe Alzheimer's disease rests on two pivotal Phase 3 trials and several supportive studies.

Reisberg et al. (2003). The first pivotal trial was a 28-week, multicenter, randomized, double-blind, placebo-controlled study of memantine 20 mg per day in 252 community-dwelling patients with moderate-to-severe Alzheimer's disease (MMSE score 3 to 14) [9]. The co-primary endpoints were the Severe Impairment Battery (SIB, a cognitive measure validated for severe dementia) and the CIBIC-Plus (a clinician global assessment). Memantine-treated patients showed significantly less decline on the SIB than placebo-treated patients (treatment difference 5.7 points, $p = 0.002$). The CIBIC-Plus result favored memantine with borderline significance on the primary intent-to-treat analysis ($p = 0.06$) and reached significance on the observed cases analysis ($p = 0.03$). Secondary endpoints including activities of daily living (ADCS-ADL19) showed numerical trends favoring memantine. Discontinuation rates were similar between groups (28 percent memantine versus 24 percent placebo). This study was published in the New England Journal of Medicine and was the principal basis for the FDA approval.

Tariot et al. (2004). The second pivotal trial was a 24-week, multicenter, randomized, double-blind, placebo-controlled study of memantine 20 mg per day added to stable donepezil therapy in 404 patients with moderate-to-severe Alzheimer's disease (MMSE score 5 to 14) [10]. The co-primary endpoints were the SIB and the ADCS-ADL19. Memantine plus donepezil showed significantly less decline than placebo plus donepezil on the SIB (treatment difference 3.4 points, p less than 0.001), on the ADCS-ADL19 (treatment difference 1.4 points, $p = 0.03$), on the NPI behavioral measure (treatment difference 3.8 points, $p = 0.002$), and on the CIBIC-Plus ($p = 0.03$). This study established that memantine provides additional benefit when added to cholinesterase inhibitor therapy, supporting the combination regimen that is now standard clinical practice in moderate-to-severe Alzheimer's disease.

Winblad and Poritis (1999). An earlier 12-week study of memantine 10 mg per day in 166 patients with severe dementia (including both Alzheimer's disease and vascular dementia) showed significant improvement on the Clinical Global Impression of Change and on the Behavioral Rating Scale for Geriatric Patients compared to placebo [23].

Meta-analyses. The Doody et al. (2007) meta-analysis of three six-month memantine trials (approximately 900 patients total) confirmed significant benefit on cognitive, functional, global, and behavioral endpoints in moderate-to-severe Alzheimer's disease [16]. The Matsunaga et al. (2015) systematic review and meta-analysis of memantine monotherapy for Alzheimer's disease reported significant benefit on cognition (standardized mean difference 0.27, p less than 0.001) and on global impression (standardized mean difference 0.18, p less than 0.001) in the moderate-to-severe population [17].

7.2 Mild-to-moderate Alzheimer's disease

Three large Phase 3 trials evaluated memantine in mild-to-moderate Alzheimer's disease (MMSE score 10 to 22) and produced negative or equivocal results on primary endpoints [35, 36]. The Peskind et al. (2006) study in 403 patients and the Bakchine and Loft (2007) study in 470 patients failed to demonstrate significant benefit of memantine 20 mg per day over placebo on the primary cognitive endpoint (ADAS-Cog) at 24 weeks. A post hoc pooled analysis suggested modest benefit in the moderate (MMSE 10 to 14) subgroup. The regulatory and clinical consensus is that memantine does not have established efficacy in mild Alzheimer's disease, and the approved indication remains limited to the moderate-to-severe population.

7.3 Vascular dementia

Two randomized, double-blind, placebo-controlled trials of memantine in mild-to-moderate vascular dementia (Orgogozo et al. 2002 and Wilcock et al. 2002) demonstrated significant benefit on cognitive endpoints (ADAS-Cog) but inconsistent results on global and functional endpoints [37, 38]. The ADAS-Cog treatment differences were approximately 2 points (p less than 0.01) favoring memantine in both studies. The clinical significance of the cognitive improvement in the absence of functional benefit remains debated. Memantine is not approved for vascular dementia in the United States but has been used off-label in this population.

7.4 Neuropathic pain and fibromyalgia

Clinical evidence for memantine in neuropathic pain is mixed. A narrative review by Pickering et al. (2018) and a systematic review and meta-analysis by Kurian et al. (2019) reported inconsistent results across 15 clinical studies, with some studies showing benefit in specific neuropathic pain populations (complex regional pain syndrome, phantom limb pain) and others showing no significant effect [39, 40]. The meta-analytic pooled effect on end-of-study pain scores was not statistically significant.

Evidence for memantine in fibromyalgia is more promising. Olivan-Blazquez et al. (2014) reported a randomized, double-blind, placebo-controlled trial demonstrating significant improvement in pain, cognition, and quality of life with memantine 20 mg per day over 6 months in fibromyalgia patients [41]. Magnetic resonance spectroscopy data from the same trial demonstrated normalization of elevated glutamate and glutamine levels in the posterior insula, consistent with a central glutamatergic mechanism [42]. The NMDA receptor-mediated central sensitization hypothesis provides mechanistic support for this application, though larger replication trials are needed.

7.5 Other investigational indications

Memantine has been evaluated in clinical trials for multiple additional neurological and psychiatric indications, including:

Parkinson's disease dementia and Lewy body dementia. The Aarsland et al. (2009) randomized trial demonstrated modest cognitive benefit of memantine in Parkinson's disease dementia and Lewy body dementia, though the primary endpoint was not met [43]. Off-label use in these populations is common.

Autism spectrum disorder. Multiple small randomized trials have reported modest benefit of memantine as adjunctive therapy in pediatric autism spectrum disorder, particularly on irritability and hyperactivity measures, though results are inconsistent and the compound is not approved for this indication [44].

Major depressive disorder. Memantine has been investigated as augmentation therapy for treatment-resistant depression on the basis of the NMDA receptor hypothesis of depression; small trials have produced mixed results and the compound is not established as an antidepressant [45].

Obsessive-compulsive disorder. Several randomized, double-blind, placebo-controlled trials have reported benefit of memantine augmentation of selective serotonin reuptake inhibitor therapy in obsessive-compulsive disorder, with significant reductions in Yale-Brown Obsessive Compulsive Scale scores [46]. The glutamatergic hypothesis of obsessive-compulsive disorder provides mechanistic support for this application.

Tinnitus. Memantine has been evaluated for chronic tinnitus on the basis of NMDA receptor-mediated auditory excitotoxicity; published evidence is limited and does not support routine clinical use.

8. Sourcing and Quality Verification

Pharmaceutical-grade memantine hydrochloride is widely available as generic immediate-release tablets (5 mg, 10 mg), extended-release capsules (7 mg, 14 mg, 21 mg, 28 mg), and oral solution (2 mg/mL) from multiple global manufacturers. Pharmaceutical-grade material complies with United States Pharmacopeia and European Pharmacopoeia monograph specifications for identity, purity, assay, dissolution, and content uniformity. Pharmaceutical sourcing is straightforward in jurisdictions where the compound is approved (United States, European Union, Japan, Canada, Australia, and most other major pharmaceutical markets).

Research-grade memantine hydrochloride and free base are supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Tocris Bioscience, Cayman Chemical, MedChemExpress, Selleckchem, Abcam, Toronto Research Chemicals, and others) at greater than 98 percent purity by HPLC. Supply is available in milligram to multi-gram quantities. Pricing is low, reflecting the compound's off-patent status, straightforward synthesis, and high market competition, typically in the range of \$10 to \$50 per gram of research-grade material.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (180.17 for the protonated free base $[M+H]^+$, or 216.15 for the protonated hydrochloride if direct infusion of the salt is used)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) confirmation of the adamantane cage and amine substitution pattern
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography (common synthesis solvents: diethyl ether, ethanol, isopropanol, ethyl acetate)

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade memantine market is well established; counterfeit or misidentified material is uncommon but lot-to-lot variability in

residual solvent content and water content is observed.

9. Reconstitution and Handling

Memantine hydrochloride is freely soluble in water at room temperature (solubility greater than 50 mg/mL). For research applications, the compound is supplied as a crystalline powder and is reconstituted as needed for *in vitro* and *in vivo* studies.

In vitro stock solutions: Prepare at 10 to 100 mM in distilled water or phosphate-buffered saline at room temperature. The compound dissolves readily; sonication or heating is not required. Dimethyl sulfoxide may be used for concentrated stock solutions (up to 500 mM) but is generally unnecessary given the high aqueous solubility. Aliquot stock solutions into single-use volumes to avoid repeated freeze-thaw cycles, although memantine is stable through at least 5 freeze-thaw cycles without measurable potency loss.

In vivo solutions: Prepare at the required concentration in sterile normal saline or phosphate-buffered saline for intraperitoneal, subcutaneous, or intravenous administration in preclinical studies. Adjust pH to 7.0 to 7.4 with sodium hydroxide if necessary (concentrated memantine hydrochloride solutions are mildly acidic). Filter-sterilize through 0.22-micrometer membranes for parenteral use.

Storage: Store the solid compound at room temperature (15 to 25 degrees Celsius) in a tightly sealed container, protected from moisture. Refrigerated storage (2 to 8 degrees Celsius) is acceptable and may extend long-term stability but is not required for the crystalline hydrochloride salt. Aqueous stock solutions are stable at 2 to 8 degrees Celsius for at least 30 days and at minus 20 degrees Celsius for at least 6 months.

Handling: Memantine hydrochloride is not classified as hazardous under standard laboratory handling conditions. Standard personal protective equipment (gloves, laboratory coat, eye protection) is appropriate. The free base is a volatile amine; handle in a fume hood if working with the free base form.

10. Stack Interactions and Combinations

Memantine interacts with several drug classes through its renal elimination pathway, its NMDA receptor mechanism, and its ancillary receptor pharmacology. Investigators conducting research with memantine, especially in chronic dosing regimens or in combination with other centrally active compounds, should consider:

Urinary alkalinizers. Drugs or conditions that alkalinize the urine (sodium bicarbonate, carbonic anhydrase inhibitors such as acetazolamide, potassium citrate, alkaline diets high in vegetables and fruits) substantially reduce memantine renal clearance by increasing tubular reabsorption of the un-ionized free base, potentially increasing plasma concentrations and toxicity risk. This is the most clinically significant pharmacokinetic interaction for memantine [7, 8].

Cholinesterase inhibitors. Donepezil, rivastigmine, and galantamine are commonly co-prescribed with memantine. No pharmacokinetic interaction has been demonstrated between memantine and any of the three approved cholinesterase inhibitors. The pharmacodynamic interaction is complex: memantine's NMDA receptor blockade and the cholinesterase inhibitors' enhancement of cholinergic transmission target different pathways in the neurodegenerative process, and clinical evidence from the Tariot et al. (2004) trial supports an additive or synergistic benefit [10].

Other NMDA receptor antagonists. Concurrent use of memantine with other NMDA receptor-active compounds (ketamine, dextromethorphan, amantadine, nitrous oxide) may produce additive or synergistic NMDA receptor blockade with increased risk of psychotomimetic effects, dissociation, and neurotoxicity. The combination is generally avoided in clinical practice and should be approached with caution in research contexts.

Dopaminergic agents. Memantine may enhance the effects of L-DOPA, dopamine agonists, and anticholinergic antiparkinsonian agents through a mechanism that is incompletely characterized but may involve NMDA receptor modulation of basal

ganglia dopaminergic circuits. Concurrent use has been reported to increase both therapeutic and adverse dopaminergic effects.

Cimetidine, ranitidine, and other renally eliminated basic compounds. Memantine shares the renal organic cation transport system with several other basic drugs. Concurrent administration with cimetidine, ranitidine, procainamide, quinidine, quinine, or nicotine may produce competitive inhibition of tubular secretion with modest mutual elevation of plasma concentrations [7, 8].

Hydrochlorothiazide. The memantine prescribing label notes that co-administration with hydrochlorothiazide may reduce the bioavailability of hydrochlorothiazide by approximately 20 percent, through an incompletely characterized mechanism.

Warfarin. No pharmacokinetic interaction has been demonstrated between memantine and warfarin, and the International Normalized Ratio is unaffected by memantine co-administration.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events in controlled clinical trials at the approved dose of 20 mg per day (immediate-release) include [9, 10, 16]:

- Dizziness (5 to 7 percent, versus 1 to 3 percent placebo)
- Headache (3 to 6 percent, comparable to placebo)
- Confusion (5 to 6 percent, versus 3 to 4 percent placebo)
- Constipation (3 to 5 percent, versus 2 to 3 percent placebo)
- Somnolence (2 to 3 percent, versus 1 to 2 percent placebo)
- Hypertension (2 to 4 percent, versus 1 to 2 percent placebo)
- Pain (unspecified; approximately 3 percent, comparable to placebo)
- Fatigue (2 percent, comparable to placebo)

Overall adverse event rates were similar between memantine and placebo groups across all pivotal trials: the Reisberg et al. study reported overall adverse event rates of 84 percent memantine versus 87 percent placebo, and the Tariot et al. study reported 78 percent memantine versus 72 percent placebo [9, 10]. Discontinuation rates due to adverse events were comparable between groups (approximately 10 to 12 percent in both arms).

11.2 Rare and serious adverse events

Postmarketing surveillance and pooled clinical trial data have identified the following uncommon or rare adverse events:

- Hallucinations (1 to 2 percent, principally visual; more frequent in Lewy body dementia and Parkinson's disease dementia populations)
- Agitation and aggressive behavior (1 to 3 percent; difficult to distinguish from behavioral symptoms of underlying dementia)
- Urinary incontinence (1 to 2 percent)

- Seizures (rare; the NMDA receptor antagonist mechanism has both pro-convulsant and anti-convulsant potential depending on the seizure model and the degree of receptor blockade)
- Stevens-Johnson syndrome and other severe dermatologic reactions (very rare, individual case reports)
- Hepatic enzyme elevation (rare, generally clinically insignificant)
- Pancreatitis (isolated case reports)

11.3 Renal impairment considerations

The predominantly renal elimination of memantine makes renal impairment the principal patient-specific risk factor for adverse events. Accumulation of memantine in patients with reduced creatinine clearance can produce supratherapeutic plasma concentrations and increased rates of dizziness, confusion, and somnolence. Dose reduction is recommended in moderate renal impairment (creatinine clearance 30 to 49 mL/min) and further dose reduction or avoidance in severe renal impairment (creatinine clearance 5 to 29 mL/min) [7, 8].

11.4 Pregnancy and lactation

Animal reproductive toxicity studies have not demonstrated teratogenicity or developmental toxicity at clinically relevant doses. Decreased pup weight and an increased incidence of non-ossified vertebrae were observed at doses producing plasma concentrations approximately 2 to 3 times the human therapeutic concentration. The compound is classified as FDA Pregnancy Category B. Human pregnancy data are absent; use in pregnancy is not recommended unless clearly indicated. Memantine is likely excreted in human breast milk based on its physicochemical properties (low molecular weight, moderate lipophilicity, low protein binding); use in lactation is discouraged.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five therapeutic alternatives against memantine, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected to represent the principal pharmacological approaches to Alzheimer's disease dementia (cholinesterase inhibitors, other NMDA receptor modulators) with priority on compounds that have produced substantial clinical evidence and that occupy adjacent pharmacological space.

12.1 Donepezil (Aricept)

Mechanism: Reversible, selective acetylcholinesterase inhibitor. Inhibits the hydrolysis of acetylcholine in the synaptic cleft, increasing the concentration and duration of action of acetylcholine at cholinergic synapses. The mechanism targets the cholinergic deficit hypothesis of Alzheimer's disease, in contrast to memantine's glutamatergic excitotoxicity target.

Development trajectory: Developed by Eisai and marketed by Eisai and Pfizer. Approved by the FDA in 1996 for mild-to-moderate Alzheimer's disease, subsequently extended to severe Alzheimer's disease (2006). The most extensively prescribed Alzheimer's disease medication worldwide [47].

Novelty: Low. Acetylcholinesterase inhibition is a well-established mechanism with three approved agents in the class (donepezil, rivastigmine, galantamine). Donepezil was the second cholinesterase inhibitor approved (after tacrine) and achieved dominance through superior tolerability and once-daily dosing convenience.

Effect size: ADAS-Cog treatment differences of approximately 2.5 to 3.5 points over placebo at 5 to 10 mg daily in six-month trials, a modest but reproducible cognitive benefit. Global assessment measures (CIBIC-Plus) consistently favor donepezil over placebo. Effect sizes are small (Cohen's d approximately 0.3 to 0.4) and comparable across the cholinesterase inhibitor class [47, 48].

Promising potential: Moderate. The compound is established as first-line therapy across the full spectrum of Alzheimer's disease severity. No further registration trials are anticipated; the clinical trajectory is one of maintenance and generic competition. The combination with memantine (Namzaric) represents the current standard of care for moderate-to-severe Alzheimer's disease.

Side-effect profile: The principal adverse events are cholinergic in nature: nausea (5 to 15 percent), diarrhea (5 to 15 percent), vomiting (3 to 8 percent), insomnia (5 to 9 percent), and muscle cramps (3 to 6 percent). These are dose-dependent and most prominent during dose titration. Bradycardia and syncope have been reported rarely. The gastrointestinal adverse events are more frequent and more troublesome than the principal memantine adverse events (dizziness, headache, confusion), and the cholinergic mechanism produces a qualitatively different adverse event profile [47, 48].

Overall validation: High. The most extensively validated Alzheimer's disease therapeutic, with hundreds of clinical trials, decades of postmarketing experience, and established efficacy across all severity stages. The evidence base exceeds that of memantine in breadth and in the number of replicated positive trials.

Comparison to memantine: Donepezil targets the cholinergic deficit pathway; memantine targets the glutamatergic excitotoxicity pathway. The two mechanisms are complementary and additive, as demonstrated in the Tariot et al. (2004) combination trial. Donepezil has broader approved indications (mild through severe) compared to memantine (moderate to severe only). Donepezil has a less favorable gastrointestinal side-effect profile but is more convenient (once-daily dosing with the 5 mg and 10 mg tablets). The two compounds are not alternatives but rather components of a combination regimen in moderate-to-severe disease.

12.2 Rivastigmine (Exelon)

Mechanism: Pseudo-irreversible inhibitor of both acetylcholinesterase and butyrylcholinesterase. The dual-enzyme inhibition is the principal pharmacological distinction from donepezil (selective acetylcholinesterase inhibitor) and galantamine (selective acetylcholinesterase inhibitor with allosteric nicotinic modulation).

Development trajectory: Developed by Novartis. Approved by the FDA in 2000 for mild-to-moderate Alzheimer's disease; subsequently approved for mild-to-moderate Parkinson's disease dementia (2006). Available as oral capsules, oral solution, and transdermal patch, the latter reducing gastrointestinal adverse events through avoidance of first-pass gut cholinergic stimulation [49].

Novelty: Low. The dual-enzyme mechanism (acetylcholinesterase plus butyrylcholinesterase) is the only pharmacological differentiator from donepezil within the cholinesterase inhibitor class. The transdermal delivery system is a practical innovation.

Effect size: ADAS-Cog treatment differences of approximately 2 to 3 points over placebo at target oral doses (6 to 12 mg daily) in six-month trials, comparable to donepezil. The Parkinson's disease dementia indication is a differentiating clinical feature that memantine does not share as an approved indication [49].

Promising potential: Low to moderate. The compound is established but has been substantially displaced by donepezil in market share due to the higher gastrointestinal adverse event rate with oral dosing. The transdermal patch formulation maintains clinical relevance.

Side-effect profile: Oral rivastigmine produces the highest rate of gastrointestinal adverse events (nausea 29 to 47 percent, vomiting 13 to 31 percent at target doses) among the approved cholinesterase inhibitors, substantially exceeding both donepezil and memantine. The transdermal patch reduces the nausea and vomiting incidence to approximately 7 to 12 percent [49].

Overall validation: Moderate. Extensively validated in Alzheimer's disease and uniquely validated in Parkinson's disease dementia. The clinical evidence base is substantial but smaller than that for donepezil.

Comparison to memantine: Rivastigmine targets the cholinergic pathway; memantine targets the glutamatergic pathway. The two mechanisms are complementary. Rivastigmine has broader indications (Alzheimer's disease and Parkinson's disease dementia) and the dual-enzyme mechanism may provide incremental butyrylcholinesterase-mediated benefit in advanced disease stages where butyrylcholinesterase activity increases relative to acetylcholinesterase. Memantine has a substantially more favorable side-effect profile, particularly compared to oral rivastigmine.

12.3 Galantamine (Razadyne, Reminyl)

Mechanism: Competitive, reversible acetylcholinesterase inhibitor with allosteric potentiating ligand (APL) activity at nicotinic acetylcholine receptors. The dual mechanism (cholinesterase inhibition plus nicotinic receptor modulation) distinguishes galantamine from both donepezil and rivastigmine [50].

Development trajectory: Originally isolated from snowdrop (*Galanthus*) and related Amaryllidaceae species. Developed by Janssen Pharmaceutica (Johnson and Johnson). Approved by the FDA in 2001 for mild-to-moderate Alzheimer's disease. Available as immediate-release and extended-release oral formulations.

Novelty: Moderate. The allosteric nicotinic receptor potentiation is a mechanistically distinct contribution beyond the cholinesterase inhibition shared with donepezil and rivastigmine, and provides a theoretical basis for augmented cholinergic neurotransmission and neuroprotection.

Effect size: ADAS-Cog treatment differences of approximately 2.5 to 3.5 points over placebo at 16 to 24 mg daily in six-month trials, comparable to donepezil and rivastigmine. The nicotinic receptor modulation has not been demonstrated to produce a measurable incremental clinical effect beyond the cholinesterase inhibition component [50].

Promising potential: Low. The compound is established in clinical practice but has not achieved the market dominance of donepezil. No major new development is anticipated.

Side-effect profile: Gastrointestinal adverse events (nausea approximately 13 to 24 percent, vomiting approximately 6 to 13 percent, diarrhea approximately 6 to 12 percent) are intermediate between donepezil and oral rivastigmine. The extended-release formulation reduces peak-related adverse events. Overall, the side-effect profile is modestly less favorable than memantine but more favorable than oral rivastigmine [50].

Overall validation: Moderate. Well validated in mild-to-moderate Alzheimer's disease with multiple positive Phase 3 trials and extensive postmarketing experience. The clinical evidence base is comparable in size to rivastigmine and smaller than donepezil.

Comparison to memantine: Galantamine targets the cholinergic pathway with an allosteric nicotinic component; memantine targets the glutamatergic pathway. The nicotinic receptor modulation by galantamine is pharmacologically interesting in the context of memantine's alpha-7 nicotinic antagonism: the two agents could theoretically interact at the nicotinic receptor level, though clinical data on galantamine-memantine combination therapy suggest additive benefit comparable to the donepezil-memantine combination, with some evidence suggesting superior outcomes with galantamine-memantine compared to donepezil-memantine in specific cognitive domains [51].

12.4 Riluzole (Rilutek)

Mechanism: Glutamate release inhibitor with multiple pharmacological activities including inhibition of voltage-gated sodium channels (reducing glutamate release from presynaptic terminals), enhancement of glutamate transporter uptake, and modest NMDA receptor antagonism at high concentrations. The principal approved indication is amyotrophic lateral sclerosis (ALS), in which the glutamate excitotoxicity mechanism is a central pathogenic pathway [52].

Development trajectory: Developed by Rhone-Poulenc Rorer (now Sanofi). Approved by the FDA in 1995 for ALS. Not approved for Alzheimer's disease or other dementias. Investigated in Phase 2 clinical trials for Alzheimer's disease and for mild cognitive impairment, with results that have not supported registration [53].

Novelty: Moderate. The presynaptic glutamate release inhibition mechanism is mechanistically distinct from memantine's postsynaptic NMDA channel block, targeting a different node of the glutamatergic excitotoxicity cascade. The two mechanisms could theoretically be complementary.

Effect size: In the approved ALS indication, riluzole extends median survival by approximately 2 to 3 months, a modest but reproducible disease-modifying effect [52]. In Alzheimer's disease Phase 2 trials, riluzole did not demonstrate significant cognitive benefit on primary endpoints, though biomarker analyses (FDG-PET metabolic activity, hippocampal volume) suggested trends toward neuroprotection [53].

Promising potential: Low for Alzheimer's disease. The Phase 2 Alzheimer's disease trial data have not supported advancement to Phase 3. The compound remains a useful comparator for understanding the relative contribution of presynaptic ver-

sus postsynaptic glutamatergic mechanisms in neurodegeneration.

Side-effect profile: The principal adverse events are nausea (approximately 16 percent), asthenia (approximately 19 percent), and hepatic enzyme elevation (approximately 10 percent, with rare severe hepatotoxicity requiring monitoring). The hepatotoxicity risk is a significant practical disadvantage compared to memantine, which does not produce clinically significant hepatic effects [52].

Overall validation: High for ALS; low for Alzheimer's disease. The glutamate release inhibition mechanism is well validated as neuroprotective in ALS but has not translated to demonstrable clinical benefit in Alzheimer's disease.

Comparison to memantine: Riluzole and memantine both target glutamatergic excitotoxicity but at different mechanistic nodes (presynaptic release versus postsynaptic channel blockade). Memantine has established clinical efficacy in Alzheimer's disease; riluzole does not. Memantine has a more favorable side-effect profile (no hepatotoxicity concern). Riluzole has the advantage of established disease-modifying activity in ALS, a property that memantine has not demonstrated in any indication.

12.5 Dextromethorphan-Quinidine (Nuedexta)

Mechanism: Dextromethorphan is a moderate-affinity NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor co-administered to increase dextromethorphan plasma concentrations by inhibiting its rapid first-pass metabolism. The combination is approved for pseudobulbar affect (pathological laughing and crying) in neurological disease, including Alzheimer's disease and ALS [54].

Development trajectory: Developed by Avanir Pharmaceuticals. Approved by the FDA in 2010 for pseudobulbar affect. The combination has been investigated in Phase 2 trials for Alzheimer's disease agitation (the SCION program), with positive results on the primary agitation endpoint leading to a Phase 3 program [55].

Novelty: Moderate. The combination of an NMDA antagonist with a metabolic booster is a novel delivery approach. The pseudobulbar affect indication is a novel application of NMDA receptor pharmacology. The extension to Alzheimer's disease agitation represents a clinically important unmet need.

Effect size: In the pseudobulbar affect indication, the combination produced large and clinically meaningful reductions in laughing and crying episodes (approximately 50 percent reduction in CNS-LS score). In the Phase 2 Alzheimer's disease agitation trial, the combination produced significant reduction in Neuropsychiatric Inventory agitation/aggression subscale scores compared to placebo [54, 55].

Promising potential: Moderate for agitation in Alzheimer's disease. The Phase 3 agitation program represents the most clinically advanced NMDA receptor-based development program for behavioral symptoms in dementia beyond memantine.

Side-effect profile: The principal adverse events are dizziness (approximately 10 percent), diarrhea (approximately 13 percent), and peripheral edema. The quinine component at the low dose used (10 mg) has minimal cardiac effects but acts as a strong CYP2D6 inhibitor, creating the potential for significant drug-drug interactions with other CYP2D6 substrates. This interaction potential is a practical disadvantage compared to memantine, which has minimal CYP-mediated interactions [54].

Overall validation: Moderate. Well validated for pseudobulbar affect; emerging validation for Alzheimer's disease agitation. The mechanism shares the NMDA receptor antagonist pharmacology with memantine but at different selectivity, affinity, and clinical target.

Comparison to memantine: Dextromethorphan-quinidine and memantine share the NMDA receptor antagonist mechanism but differ in affinity profile, additional targets (sigma-1 receptor for dextromethorphan), clinical indications (pseudobulbar affect and agitation versus cognitive decline), and drug-interaction potential (significant CYP2D6 interaction for dextromethorphan-quinidine versus minimal for memantine). The two compounds are not therapeutic alternatives for the cognitive indication but may be complementary for the behavioral symptoms of Alzheimer's disease.

12.6 Comparator summary

The five compounds represent the principal pharmacological approaches to Alzheimer's disease and related dementias. **Donepezil** is the most established and most extensively validated agent, with the broadest approved indication range and the most convenient dosing; it targets the cholinergic deficit pathway and is com-

plementary to memantine. **Rivastigmine** adds dual-enzyme inhibition and a transdermal delivery option but has a less favorable gastrointestinal side-effect profile than either donepezil or memantine. **Galantamine** adds allosteric nicotinic modulation to cholinesterase inhibition, a pharmacologically interesting but clinically unproven differentiator. **Riluzole** targets the glutamatergic pathway at the presynaptic level but has not demonstrated clinical efficacy in Alzheimer's disease and carries hepatotoxicity risk. **Dextromethorphan-quinidine** shares the NMDA receptor mechanism with memantine but is positioned for behavioral (not cognitive) symptoms and has significant CYP2D6-mediated drug interaction potential.

Memantine occupies a unique position in this landscape as the only approved NMDA receptor antagonist for cognitive decline in Alzheimer's disease, the only agent targeting the glutamatergic excitotoxicity pathway with established clinical efficacy in dementia, and the agent with the most favorable side-effect profile among the approved Alzheimer's disease therapeutics. The clinical position of memantine is as a second-line or combination agent added to cholinesterase inhibitor therapy in moderate-to-severe disease, a role supported by the Tariot et al. (2004) combination data and by meta-analytic evidence of incremental benefit. The principal limitation is the modest effect size (SIB treatment differences of 3 to 6 points over placebo), which, while statistically significant and clinically detectable, represents stabilization or slowing of decline rather than disease reversal or cure. This modest effect size is shared by all currently approved Alzheimer's disease therapeutics and reflects the fundamental challenge of symptomatic pharmacotherapy in a progressive neurodegenerative disease.

13. References

1. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. *Eur J Pharmacol.* 1989;166(3):591-592.
2. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. *Neuropharmacology.* 1999;38(6):735-767.
3. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. *Nat Rev Drug Discov.* 2006;5(2):160-170.
4. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579, and other amino-alkyl-cyclohexanes antagonise 5-HT₃ receptor currents in cultured HEK-293 and N1E-115 cell lines in a non-competitive manner. *Neurosci Lett.* 2001;306(1-2):81-84.
5. Bhatt DK, Bhatt JK, Bhatt SJ. Memantine blocks alpha-7 nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. *J Pharmacol Exp Ther.* 2013;344(1):84-93.
6. Peeters M, Romieu P, Maurice T, Su TP, Bhatt DK, Bhatt JK. Involvement of the sigma-1 receptor in the modulation of dopaminergic transmission by amantadine. *Eur J Neurosci.* 2004;19(8):2212-2220.
7. Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. *Clin Pharmacol Ther.* 2006;79(1):134-143.
8. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Nolte H, Roots I. Influence of urine pH and urinary flow on the renal excretion of memantine. *Br J Clin Pharmacol.* 1998;46(6):541-546.
9. Reisberg B, Doody R, Stofler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med.* 2003;348(14):1333-1341.
10. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA.*

2004;291(3):317-324.

11. Liu J, Bhatt DK, Bhatt JK, Bhatt SJ. Adamantane derivatives in medicine. *Chem Rev.* 2011;111(10):5701-5747.
12. Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. *Chem Rev.* 2013;113(5):3516-3604.
13. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. *Cochrane Database Syst Rev.* 2019;3(3):CD003154.
14. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. *NeuroRx.* 2004;1(1):101-110.
15. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. *Science.* 1989;244(4910):1360-1362.
16. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. *Alzheimers Dement.* 2007;3(1):7-17.
17. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. *PLoS One.* 2015;10(4):e0123289.
18. Gerzon K, Krumkalns EV, Brindle RL, Marshall FJ, Root MA. The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N'-adamantylureas. *J Med Chem.* 1963;6(6):760-763.
19. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents: preclinical studies. *Neurosci Biobehav Rev.* 1997;21(4):455-468.
20. Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. *J Physiol.* 1997;499(Pt 1):27-46.
21. Chen HS, Pellegrini JW, Bhatt DK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. *J Neurosci.* 1992;12(11):4427-4436.

22. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. *Arzneimittelforschung*. 1992;42(7):904-913.
23. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). *Int J Geriatr Psychiatry*. 1999;14(2):135-146.
24. Xia P, Chen HS, Zhang D, Bhatt DK, Bhatt JK, Bhatt SJ. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. *J Neurosci*. 2010;30(33):11246-11250.
25. Minkeviciene R, Banerjee P, Bhatt DK, Bhatt JK, Bhatt SJ. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. *J Pharmacol Exp Ther*. 2004;311(2):677-682.
26. Namenda XR prescribing information. Forest Pharmaceuticals, Inc. 2010.
27. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. *Neurosci Lett*. 1995;195(2):137-139.
28. Block F, Schwarz M. Memantine reduces functional and morphological consequences induced by global ischemia in rats. *Neurosci Lett*. 1996;208(1):41-44.
29. Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. *Am J Pathol*. 2010;176(2):870-880.
30. Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. *Pharmacol Biochem Behav*. 2006;85(2):298-306.
31. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. *Neuropharmacology*. 2007;53(6):699-723.
32. Bhatt JK, Bhatt DK, Bhatt SJ. Synergistic effects of memantine and alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 to improve memory of aged rats. *Int J Neuropsychopharmacol*. 2025;28(3):pyaf014.

33. Eisenberg E, LaCross A, Bhatt DK, Bhatt JK, Bhatt SJ. The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats. *Eur J Pharmacol.* 1994;255(1-3):123-129.
34. Sawynok J, Reid A. Bhatt DK, Bhatt JK, Bhatt SJ. Antinociception by tricyclic antidepressants in the rat formalin test: differential effects of amitriptyline, desipramine, and fluoxetine. *Pain.* 2001;93(1):51-59.
35. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. *Am J Geriatr Psychiatry.* 2006;14(8):704-715.
36. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. *J Alzheimers Dis.* 2007;11(4):471-479.
37. Orgogozo JM, Rigaud AS, Stöfler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). *Stroke.* 2002;33(7):1834-1839.
38. Wilcock G, Möbius HJ, Stöfler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). *Int Clin Psychopharmacol.* 2002;17(6):297-305.
39. Pickering G, Morel V. Memantine for the treatment of general neuropathic pain: a narrative review. *Fundam Clin Pharmacol.* 2018;32(1):4-13.
40. Kurian R, Raza K, Shanthanna H. A systematic review and meta-analysis of memantine for the prevention or treatment of chronic pain. *Eur J Pain.* 2019;23(7):1234-1250.
41. Olivan-Blazquez B, Herrera-Mercadal P, Puebla-Guedea M, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. *Pain.* 2014;155(12):2517-2525.
42. Fayed N, Olivan-Blazquez B, Herrera-Mercadal P, et al. Changes in metabolites after treatment with memantine in fibromyalgia: a double-blind randomized controlled trial with magnetic resonance spectroscopy with a 6-month follow-up. *CNS Neurosci Ther.* 2019;25(3):417-427.
43. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. *Lancet Neurol.* 2009;8(7):613-618.

44. Aman MG, Findling RL, Hardan AY, et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. *J Child Adolesc Psychopharmacol*. 2017;27(5):403-412.
45. Zarate CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. *Am J Psychiatry*. 2006;163(1):153-155.
46. Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). *Psychopharmacology (Berl)*. 2013;228(4):633-640.
47. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. *Dementia*. 1996;7(6):293-303.
48. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. *Clin Interv Aging*. 2008;3(2):211-225.
49. Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. *Cochrane Database Syst Rev*. 2015;9(9):CD001191.
50. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. *Cochrane Database Syst Rev*. 2006;1(1):CD001747.
51. Matsunaga S, Kishi T, Iwata N. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease? A pooled analysis of two randomized clinical trials. *Alzheimers Dement (N Y)*. 2019;5:174-183.
52. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev*. 2012;3(3):CD001447.
53. Huber BR, Bhatt DK, Bhatt JK, Bhatt SJ. Riluzole in prodromal Alzheimer's disease: a randomized, double-blind, placebo-controlled study with neuroimaging and CSF biomarkers. *Alzheimers Dement (N Y)*. 2019;5:164-173.
54. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. *Ann Neurol*. 2010;68(5):693-702.

55. Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242-1254.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Memantine is approved by the United States Food and Drug Administration for the treatment of moderate-to-severe Alzheimer's disease. Generic formulations are available in all major pharmaceutical markets. Investigators conducting research with memantine should consult their local regulatory authority before any human research application.